Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine

Ki Wook Yun; Hoan Jong Lee; Ji Young Park; Hye Kyung Cho; Yae Jean Kim; Kyung Hyo Kim; Nam Hee Kim; Young Jin Hong; Dong Ho Kim; Hwang Min Kim; Sung Ho Cha

doi:10.1016/j.vaccine.2018.01.075

Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine

Ki Wook Yun
, Hoan Jong Lee
, Ji Young Park
, Hye Kyung Cho
, Yae Jean Kim
, Kyung Hyo Kim
, Nam Hee Kim
, Young Jin Hong
, Dong Ho Kim
, Hwang Min Kim
, Sung Ho Cha

Seoul National University
Sungkyunkwan University
Gachon University
Ewha Womans University
Inje University
Inha University
Korea Institute of Radiological and Medical Sciences
Yonsei University Wonju College of Medicine
Kyung Hee University

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Background: This study was performed with the aim of determining the long-term immunogenicity of an inactivated, Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) and an inactivated, mouse brain-derived JE vaccine (JE-MB) after the 1st booster dose at 2 years of age, as well as the safety and immunogenicity of the 2nd booster dose of JE-VC at 6 years of age, in children primed and given a 1st booster dose of either JE-VC or JE-MB. Method: In this multicenter, open-label clinical trial, the study population consisted of healthy Korean children (aged 6 years) who participated in the previous JE vaccine trial. All subjects were subcutaneously vaccinated once for the booster immunization with Boryung Cell Culture Japanese Encephalitis Vaccine® (JE-VC). Result: Approximately 4 years after the 1st booster dose of JE-VC, the seroprotection rate (SPR) and geometric mean titer (GMT) of the neutralizing antibody were 100% and 1113.8, respectively. In children primed and given a 1st booster dose of JE-MB, the SPR and GMT were 88.5% and 56.3, respectively. After the 2nd booster dose of JE-VC, all participants primed and given a 1st booster dose of either JE-MB or JE-VC were seroprotective against JE virus. The GMT of the neutralizing antibody was higher in children primed and given a 1st booster dose of JE-VC (8144.1) than in those primed and given a 1st booster dose of JE-MB (942.5) after the vaccination (p < 0.001). In addition, the 2nd booster dose of JE-VC showed a good safety profile with no serious vaccine-related adverse events. Conclusion: The 1st booster dose of JE-VC and JE-MB showed long-term immunogenicity of at least 4 years, and the 2nd booster dose of JE-VC showed a good safety and immunogenicity profile in children primed and given a 1st booster dose of either JE-VC or JE-MB. ClinicalTtrials.gov

Original language	English
Pages (from-to)	1398-1404
Number of pages	7
Journal	Vaccine
Volume	36
Issue number	11
DOIs	https://doi.org/10.1016/j.vaccine.2018.01.075
State	Published - 7 Mar 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Children
Clinical trial
Japanese encephalitis
Vaccine
Vero cells

Access to Document

10.1016/j.vaccine.2018.01.075

Fingerprint

Dive into the research topics of 'Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine'. Together they form a unique fingerprint.

Cite this

Yun, K. W., Lee, H. J., Park, J. Y., Cho, H. K., Kim, Y. J., Kim, K. H., Kim, N. H., Hong, Y. J., Kim, D. H., Kim, H. M., & Cha, S. H. (2018). Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine. Vaccine, 36(11), 1398-1404. https://doi.org/10.1016/j.vaccine.2018.01.075

Yun, Ki Wook ; Lee, Hoan Jong ; Park, Ji Young et al. / Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine. In: Vaccine. 2018 ; Vol. 36, No. 11. pp. 1398-1404.

@article{0fe0089321ec410e99a4127a5e7e6b06,

title = "Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine",

abstract = "Background: This study was performed with the aim of determining the long-term immunogenicity of an inactivated, Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) and an inactivated, mouse brain-derived JE vaccine (JE-MB) after the 1st booster dose at 2 years of age, as well as the safety and immunogenicity of the 2nd booster dose of JE-VC at 6 years of age, in children primed and given a 1st booster dose of either JE-VC or JE-MB. Method: In this multicenter, open-label clinical trial, the study population consisted of healthy Korean children (aged 6 years) who participated in the previous JE vaccine trial. All subjects were subcutaneously vaccinated once for the booster immunization with Boryung Cell Culture Japanese Encephalitis Vaccine{\textregistered} (JE-VC). Result: Approximately 4 years after the 1st booster dose of JE-VC, the seroprotection rate (SPR) and geometric mean titer (GMT) of the neutralizing antibody were 100\% and 1113.8, respectively. In children primed and given a 1st booster dose of JE-MB, the SPR and GMT were 88.5\% and 56.3, respectively. After the 2nd booster dose of JE-VC, all participants primed and given a 1st booster dose of either JE-MB or JE-VC were seroprotective against JE virus. The GMT of the neutralizing antibody was higher in children primed and given a 1st booster dose of JE-VC (8144.1) than in those primed and given a 1st booster dose of JE-MB (942.5) after the vaccination (p < 0.001). In addition, the 2nd booster dose of JE-VC showed a good safety profile with no serious vaccine-related adverse events. Conclusion: The 1st booster dose of JE-VC and JE-MB showed long-term immunogenicity of at least 4 years, and the 2nd booster dose of JE-VC showed a good safety and immunogenicity profile in children primed and given a 1st booster dose of either JE-VC or JE-MB. ClinicalTtrials.gov",

keywords = "Children, Clinical trial, Japanese encephalitis, Vaccine, Vero cells",

author = "Yun, \{Ki Wook\} and Lee, \{Hoan Jong\} and Park, \{Ji Young\} and Cho, \{Hye Kyung\} and Kim, \{Yae Jean\} and Kim, \{Kyung Hyo\} and Kim, \{Nam Hee\} and Hong, \{Young Jin\} and Kim, \{Dong Ho\} and Kim, \{Hwang Min\} and Cha, \{Sung Ho\}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",

year = "2018",

month = mar,

day = "7",

doi = "10.1016/j.vaccine.2018.01.075",

language = "English",

volume = "36",

pages = "1398--1404",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "11",

}

Yun, KW, Lee, HJ, Park, JY, Cho, HK, Kim, YJ, Kim, KH, Kim, NH, Hong, YJ, Kim, DH, Kim, HM & Cha, SH 2018, 'Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine', Vaccine, vol. 36, no. 11, pp. 1398-1404. https://doi.org/10.1016/j.vaccine.2018.01.075

Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine. / Yun, Ki Wook; Lee, Hoan Jong; Park, Ji Young et al.
In: Vaccine, Vol. 36, No. 11, 07.03.2018, p. 1398-1404.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine

AU - Yun, Ki Wook

AU - Lee, Hoan Jong

AU - Park, Ji Young

AU - Cho, Hye Kyung

AU - Kim, Yae Jean

AU - Kim, Kyung Hyo

AU - Kim, Nam Hee

AU - Hong, Young Jin

AU - Kim, Dong Ho

AU - Kim, Hwang Min

AU - Cha, Sung Ho

PY - 2018/3/7

Y1 - 2018/3/7

N2 - Background: This study was performed with the aim of determining the long-term immunogenicity of an inactivated, Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) and an inactivated, mouse brain-derived JE vaccine (JE-MB) after the 1st booster dose at 2 years of age, as well as the safety and immunogenicity of the 2nd booster dose of JE-VC at 6 years of age, in children primed and given a 1st booster dose of either JE-VC or JE-MB. Method: In this multicenter, open-label clinical trial, the study population consisted of healthy Korean children (aged 6 years) who participated in the previous JE vaccine trial. All subjects were subcutaneously vaccinated once for the booster immunization with Boryung Cell Culture Japanese Encephalitis Vaccine® (JE-VC). Result: Approximately 4 years after the 1st booster dose of JE-VC, the seroprotection rate (SPR) and geometric mean titer (GMT) of the neutralizing antibody were 100% and 1113.8, respectively. In children primed and given a 1st booster dose of JE-MB, the SPR and GMT were 88.5% and 56.3, respectively. After the 2nd booster dose of JE-VC, all participants primed and given a 1st booster dose of either JE-MB or JE-VC were seroprotective against JE virus. The GMT of the neutralizing antibody was higher in children primed and given a 1st booster dose of JE-VC (8144.1) than in those primed and given a 1st booster dose of JE-MB (942.5) after the vaccination (p < 0.001). In addition, the 2nd booster dose of JE-VC showed a good safety profile with no serious vaccine-related adverse events. Conclusion: The 1st booster dose of JE-VC and JE-MB showed long-term immunogenicity of at least 4 years, and the 2nd booster dose of JE-VC showed a good safety and immunogenicity profile in children primed and given a 1st booster dose of either JE-VC or JE-MB. ClinicalTtrials.gov

AB - Background: This study was performed with the aim of determining the long-term immunogenicity of an inactivated, Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) and an inactivated, mouse brain-derived JE vaccine (JE-MB) after the 1st booster dose at 2 years of age, as well as the safety and immunogenicity of the 2nd booster dose of JE-VC at 6 years of age, in children primed and given a 1st booster dose of either JE-VC or JE-MB. Method: In this multicenter, open-label clinical trial, the study population consisted of healthy Korean children (aged 6 years) who participated in the previous JE vaccine trial. All subjects were subcutaneously vaccinated once for the booster immunization with Boryung Cell Culture Japanese Encephalitis Vaccine® (JE-VC). Result: Approximately 4 years after the 1st booster dose of JE-VC, the seroprotection rate (SPR) and geometric mean titer (GMT) of the neutralizing antibody were 100% and 1113.8, respectively. In children primed and given a 1st booster dose of JE-MB, the SPR and GMT were 88.5% and 56.3, respectively. After the 2nd booster dose of JE-VC, all participants primed and given a 1st booster dose of either JE-MB or JE-VC were seroprotective against JE virus. The GMT of the neutralizing antibody was higher in children primed and given a 1st booster dose of JE-VC (8144.1) than in those primed and given a 1st booster dose of JE-MB (942.5) after the vaccination (p < 0.001). In addition, the 2nd booster dose of JE-VC showed a good safety profile with no serious vaccine-related adverse events. Conclusion: The 1st booster dose of JE-VC and JE-MB showed long-term immunogenicity of at least 4 years, and the 2nd booster dose of JE-VC showed a good safety and immunogenicity profile in children primed and given a 1st booster dose of either JE-VC or JE-MB. ClinicalTtrials.gov

KW - Children

KW - Clinical trial

KW - Japanese encephalitis

KW - Vaccine

KW - Vero cells

UR - https://www.scopus.com/pages/publications/85041510649

U2 - 10.1016/j.vaccine.2018.01.075

DO - 10.1016/j.vaccine.2018.01.075

M3 - Article

C2 - 29429815

AN - SCOPUS:85041510649

SN - 0264-410X

VL - 36

SP - 1398

EP - 1404

JO - Vaccine

JF - Vaccine

IS - 11

ER -